| Document |
Document Title |
|
WO/2024/098209A1 |
A group of diagnostic biomarkers usable for diagnosis of colorectal cancer or advanced colorectal adenoma (CRC/ACRA) is provided. The method for detecting CRC/ACRA using the group of diagnostic biomarkers is also provided. For example, t...
|
|
WO/2024/102068A1 |
A computer implemented method for obtaining concentration of a volatile organic compound in an exhaled breath is described. In an embodiment, the computer- implemented method comprises: receiving a mass spectrum of an exhaled breath samp...
|
|
WO/2024/100668A1 |
Methods for assessment and monitoring of mood in subjects with bipolar disorder are provided, based on changes in the level of cortisol in hair samples of patients. In particular, methods for assessment of depression and anxiety in subje...
|
|
WO/2024/101823A1 |
The present invention relates to a biomarker for predicting immunotherapeutic responsiveness based on spatial transcriptome analysis and uses thereof and, in particular, to: a marker composition for predicting the responsiveness of cance...
|
|
WO/2024/102984A1 |
The disclosure relates to isolated nucleic acids comprising opioid receptor promoter regions and methods and compositions comprising said isolated nucleic acids.
|
|
WO/2024/101762A1 |
The present invention relates to an antibody specifically binding to SARS-CoV-1, or an antigen-binding fragment thereof. The antibody is selected from the group consisting of: a variable region comprising CDR1 of SEQ ID NO: 1, CDR2 of SE...
|
|
WO/2024/102604A1 |
Anti-5T4 antibodies and antigen-binding fragments thereof and chimeric antigen receptors (CARs) comprising anti-5T4 antigen-binding domains are described. Also described are nucleic acids encoding the antibodies and CARs, compositions co...
|
|
WO/2024/102429A1 |
In various embodiments, the present technology provides methods of reducing the risk of cardiovascular events in a subject on statin therapy and having a low baseline eicosapentaenoic acid to arachidonic acid (EPA:AA) ratio by administer...
|
|
WO/2024/100446A1 |
Provided herein are an α2-3 disialylated PSA protein standard and an α2-6 disialylated PSA protein standard, as well as various methods for measuring the relative (fractional) amount of the total N-acetylneuraminic acid (Neu5Ac) that i...
|
|
WO/2024/102360A1 |
Devices for isolating, collecting and/or transferring target molecules to an assay area, comprising an enclosure having a top section adapted to receive a sample, a central hollow body section or other area or cavity suitable for receivi...
|
|
WO/2024/097315A2 |
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g...
|
|
WO/2024/096524A1 |
The present invention is a technology related to a system for determining whether a user is abnormal by using brainwave-based complex biosignals and, on the basis of this, determining an urgent situation and an abnormal sign. During dete...
|
|
WO/2024/097970A1 |
Methods and materials for improving outcomes for ex vivo perfused organs are provided herein. For example, this document provides methods and materials that can be used to assess and treat lungs during ex vivo perfusion prior to transpla...
|
|
WO/2024/096090A1 |
Disclosed is a microphysiological system comprising a microfluidic device, and human renal proximal tubular epithelial cells (RPTEC) and pluripotent stem cell-derived LTL-positive cells which are accommodated in the microfluidic device. ...
|
|
WO/2024/092740A1 |
Provided is a method for detecting intercellular interaction. The method comprises: (1) preparing a first cell expressing a TCR activation response element and a reporter molecule, the first cell expressing a TCR; (2) co-incubating an an...
|
|
WO/2024/095740A1 |
Provided is a magnetic collecting unit that generates a magnetic field inside a reaction cell containing a suspension containing magnetic particles, to thereby collect the magnetic particles in the suspension onto the inner wall of the r...
|
|
WO/2024/093523A1 |
The present disclosure relates to methods, compositions, and kits for isolating target nucleic acids below a target size from a sample comprising nucleic acid components. In some embodiments, the methods involve one or more aqueous two-p...
|
|
WO/2024/097769A1 |
Systems, methods, and devices are disclosed for a hybrid immunoassay process. An example method includes: applying an amount of a biological sample containing analytes to a first amount of detection molecules to form a mixture of labeled...
|
|
WO/2024/094769A1 |
Method for determination of the kinetic binding parameters for a molecule binder conjugated to a fluorophore. Repeated staining of the antigen and detection of the emission radiation generates a titration series. Fitting of the emission ...
|
|
WO/2024/095582A1 |
A lubricating oil abnormality detection system (1), which is one embodiment of a lubricating oil abnormality detection system, comprises: an electrical properties acquisition unit (111) for acquiring the electrical properties of a lubric...
|
|
WO/2024/094096A1 |
Provided is a method of selecting a camelid nanobody from a library of camelid nanobody sequences collected from B cells from a camelid immunized with an antigen. The method comprises: (a) identifying a camelid nanobody that has at least...
|
|
WO/2024/094813A1 |
The present invention relates to methods of screening for osteoarthritis (OA) and rheumatoid arthritis (RA) and methods of discriminating between OA and rheumatoid arthritis RA in a subject having arthritis or in a subject suspected of h...
|
|
WO/2024/096593A1 |
Provided is a preparation method for a biomarker detector, including the steps of: preparing a reactant that chemically reacts with a biomarker; and dissolving the reactant in an acceleration solution including an accelerator for acceler...
|
|
WO/2024/094907A1 |
The invention relates to a device and method for obtaining fingerprints and characterising tissues, ideal for identifying tissues, detecting forgeries, searching for tissues with specific characteristics, quality control, and separating ...
|
|
WO/2024/097588A1 |
The present application discloses an oxygen concentration detection system for detecting the oxygen concentration in a furnace chamber of a reflow oven, comprising: a cooling device, a filter device, and a detection device. The oxygen co...
|
|
WO/2024/097357A1 |
Described herein is a method of extracting and quantitating low density lipoprotein cholesterol (LDL-C) in a blood sample. The sample is first diluted or rehydrated in a reagent 1 to provide a diluted sample. The diluted sample is then m...
|
|
WO/2024/097892A1 |
This disclosure relates to introducing specified endogenous amiRNA responsive to endogenous primary-miRNAs. This invention allows the degradation of amiRNAs in specific tissues, while allowing amiRNA to silence gene expression in other t...
|
|
WO/2024/096354A1 |
The present invention relates to a pharmaceutical composition for preventing or treating kidney cancer comprising an IFITM3 inhibitor. According to a composition according to one aspect, the tumorigenesis inhibitory effect can be induced...
|
|
WO/2024/095741A1 |
This magnetic collecting unit generates a magnetic field inside a reaction cell accommodating a suspension including magnetic particles, and causes the magnetic particles in the suspension to collect magnetically on an inner wall surface...
|
|
WO/2024/093662A1 |
A gas detection device (100), comprising: a detection unit (21) comprising a detection housing (201) and having a gas chamber (300), the detection housing (201) being at least partially positioned at the periphery of the gas chamber (300...
|
|
WO/2024/096020A1 |
According to the present invention, a examination system comprises a base portion on which a examination target object is placed, a driving device that rotates the base portion on which the examination target object has been placed, and ...
|
|
WO/2024/092985A1 |
An intrinsic fluorescence imaging detection system for protein gel electrophoresis and a method. The system comprises a portable hand-held box body (8), a chip electrophoresis device (9), an imaging detection device (5), and a computer t...
|
|
WO/2024/093042A1 |
Provided are an anti-BSA rabbit monoclonal antibody and use thereof, which belong to the technical field of antibodies. The anti-BSA rabbit monoclonal antibody or an antigen-binding portion thereof specifically binds to BSA. The monoclon...
|
|
WO/2024/092556A1 |
An electrochemiluminescent immunomagnetic chip, and an electrochemiluminescent magnetic immunoassay method combined with microfluidic technology. In view of multiple nano material enhancement signals, high-sensitivity electrochemilumines...
|
|
WO/2024/094234A1 |
A plant sap sampling device, containing • - a plant holder (4) configured to hold a plant or a plant part in a pre-determined position; • - a buffer reservoir (10); • - a sampling needle (9) movable between a sampling position in w...
|
|
WO/2024/095800A1 |
This determination method determines whether or not an object molecule containing elemental hydrogen is an electrolyzed hydrogen-containing molecule which contains a hydrogen molecule that is produced by water electrolysis or a molecule ...
|
|
WO/2024/097104A1 |
The present disclosure relates to methods of characterizing low quantities of immunogen-binding protein, e.g., immunogen-binding antibodies obtained directly from supernatants of individually cultured B cells. These methods, which avoid ...
|
|
WO/2024/097388A1 |
The present disclosure relates to methods of determining and administering a treatment course of action. In particular, the present disclosure relates to compositions and methods for monitoring and treating neurological damage (e.g., str...
|
|
WO/2024/094854A1 |
Glycated Hb was measured and compared between five healthy donors (AA), seven non-diabetic and non-transfused homozygous SCD patients (SS) and five non-diabetic, transfused SS patients. The single cell glycation was assessed by flow cyto...
|
|
WO/2024/094002A1 |
The present invention relates to a fructose diphosphate optical probe. Specifically, provided in the present invention is a fructose diphosphate optical probe, which comprises a fructose-1,6-diphosphate sensitive polypeptide and an optic...
|
|
WO/2024/097758A1 |
Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, such as an individual having a mutation within the nucleophosmin 1 (NPM1) gene or a rearrangement within the lysine[K]-methyl...
|
|
WO/2024/097263A1 |
Systems, methods, compositions, and kits for measuring secreted analytes from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and/or gene expression simultaneously....
|
|
WO/2024/096469A1 |
The present invention relates to: a diaper sensor mounted on a diaper so as to detect gases generated from urine and feces; and a patient management system using same. The present invention can accurately detect defecation in real time s...
|
|
WO/2024/098076A1 |
Aspects of the present disclosure relate generally to methods, compositions, and kits for conjugating cells with magnetic beads. Aspects of the present disclosure also include methods, compositions, and kits for using magnetic bead conju...
|
|
WO/2024/097126A1 |
A method for automatically adjusting gates to cytometry data of a target sample is provided. The method includes receiving training cytometry data corresponding to a plurality of training samples; generating an image of the target sample...
|
|
WO/2024/097844A1 |
Provided herein are extra-cellular domain Mullerian hormone receptor type II (AMHR2-ED) binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, provided herein are AMHR2-ED binding molecules (e.g....
|
|
WO/2024/096459A1 |
A method for quantitatively analyzing residual host cell proteins in order to control a biological medical product quality, according to one embodiment of the present invention, comprises steps in which: a) impurities in a biological med...
|
|
WO/2023/201564A9 |
A microwell array chip, a use method therefor, and a detection apparatus. The microwell array chip comprises a microwell array substrate, and the microwell array substrate comprises a first main surface and a second main surface disposed...
|
|
WO/2024/097571A1 |
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhib...
|
|
WO/2024/094597A1 |
The invention relates to methods for the preparation of method of preparation of Tau aggregates, including fibrils, fibrillar species, soluble and insoluble oligomeric species, new Tau aggregates and uses thereof. The invention further r...
|
